Innovotech Inc. (TSX Venture Exchange:IOT; OTCQB:IOTCF) announced today that its subsidiary, Innovotech Labs Corporation, is receiving advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The support will be used to develop new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings.
The new testing methods align with changes in international regulatory standards and address medical device manufacturers’ needs in the areas of proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development started last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand Innovotech’s service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO of Innovotech. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”
The funding comes at a critical time when medical device manufacturers face increasing scrutiny from regulators such as the U.S. Food and Drug Administration and Health Canada. The ability to provide advanced testing that simulates real-world conditions can accelerate product approvals and improve patient safety. Innovotech’s expanded services are expected to help clients navigate complex regulatory pathways and bring safer devices to market more efficiently.
Innovotech Inc. is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines deep scientific expertise with proprietary methodologies and products, including its widely used MBEC Assay® platform for high‑throughput antimicrobial and antibiotic testing. Operating through ISO‑certified and GMP‑accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision‑enabling data aligned with regulatory expectations. More information is available at https://www.innovotech.ca.
The NRC IRAP support underscores the Canadian government’s commitment to fostering innovation in the life sciences sector. By investing in antimicrobial testing services, Innovotech is poised to address a growing global need for effective infection control in healthcare settings. This development not only benefits the company’s bottom line but also has the potential to reduce healthcare-associated infections, which are a significant cause of morbidity and mortality worldwide.
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
